A Proven Drug in an Unfamiliar Specialty: Why Dermatology Has Yet to Embrace Chloroquine
There is a particular kind of medical paradox that does not involve competing evidence or unresolved clinical questions. It involves a drug with a clear mechanism, a solid body of supporting literature, an established safety profile, and an FDA-approved indication — yet one that rarely appears on a dermatologist's prescription pad. Chloroquine occupies precisely that position within American dermatology. For patients with discoid lupus erythematosus, polymorphous light eruption, and other photosensitive conditions, chloroquine represents a pharmacologically coherent and cost-effective option. That it is seldom offered reflects less about the drug's merits than about the structural peculiarities of the specialty that should be its most natural home.
The Pharmacological Case That Dermatology Largely Ignores
Chloroquine's relevance to dermatological disease is not incidental. Its immunomodulatory properties — including interference with antigen presentation, suppression of pro-inflammatory cytokine cascades, and reduction of toll-like receptor signaling — directly address the pathophysiology underlying several cutaneous autoimmune conditions. In discoid lupus erythematosus (DLE), a chronic inflammatory disorder that causes scarring skin lesions predominantly on sun-exposed areas, these mechanisms translate into measurable clinical benefit. Studies have documented lesion stabilization, reduced flare frequency, and in some patients, partial reversal of hyperpigmentation.
Beyond DLE, chloroquine has demonstrated utility in polymorphous light eruption, a condition affecting an estimated 10 to 20 percent of the North American population, and in cutaneous manifestations of systemic lupus erythematosus. Its photoprotective effect — derived in part from its ability to reduce UV-induced keratinocyte apoptosis — positions it as both a treatment and a preventive agent in photosensitive patients. This dual functionality is uncommon among dermatological therapeutics and arguably makes chloroquine more versatile than many alternatives currently in wider use.
Where Dermatology Training Falls Short
Despite this profile, chloroquine rarely receives meaningful attention in dermatology residency programs across the United States. Residency curricula are dense, and the pharmacology of antimalarial agents tends to be allocated to rheumatology rotations, where hydroxychloroquine — chloroquine's structural cousin — receives the bulk of clinical instruction. The distinction between the two compounds blurs further in practice, with many dermatology residents completing their training having encountered antimalarials only in the context of systemic lupus managed by rheumatologists.
This curricular gap has consequences that extend well beyond graduation. Clinicians who never develop fluency with a drug during training are unlikely to reach for it independently in practice, regardless of what the literature supports. Continuing medical education offerings in dermatology further compound the problem: sessions on biologics, small-molecule inhibitors, and procedural techniques dominate conference programming, while sessions on established oral agents — particularly older generics — attract minimal industry sponsorship and correspondingly modest attendance.
The result is a cohort of practicing dermatologists who may be technically aware that antimalarials exist but who lack the clinical confidence to initiate, monitor, and adjust therapy. Prescribing a drug one has never personally managed carries a cognitive weight that discourages adoption, even when evidence supports the choice.
Specialty Silos and the Turf Problem
American medicine's subspecialty architecture creates jurisdictional ambiguities that complicate care for patients with conditions that straddle disciplinary boundaries. Discoid lupus is one such condition. While its primary manifestations are cutaneous, its association with systemic lupus erythematosus means that rheumatologists often retain prescribing authority over antimalarials even when a patient is primarily being managed by a dermatologist for skin disease.
This division of responsibility is not inherently problematic, but in practice it frequently produces gaps. A dermatologist who defers antimalarial initiation to rheumatology may find that the rheumatologist, seeing no systemic disease activity, deprioritizes the referral. The patient, caught between specialties, receives topical corticosteroids as a default — a reasonable short-term measure but an insufficient long-term strategy for a condition with significant scarring potential.
The silo problem is further reinforced by how clinical guidelines are organized. Dermatology society guidelines for DLE tend to position antimalarials as second-line options, with language that implicitly assigns prescribing responsibility to rheumatology. This framing, however well-intentioned, effectively removes chloroquine from the dermatologist's active therapeutic toolkit and positions it as someone else's drug.
Aesthetic Medicine and the Culture of the New
American dermatology has undergone a significant cultural transformation over the past two decades. The rapid expansion of aesthetic and cosmetic services — injectables, laser procedures, and increasingly, biologic agents for inflammatory conditions — has reshaped the specialty's economic incentives and professional identity. Within this environment, older generic drugs occupy an awkward position. They generate minimal revenue, attract no pharmaceutical representative visits, and carry none of the prestige associated with novel therapeutics.
Biologics for conditions such as psoriasis and atopic dermatitis have become central to the dermatological identity in ways that generic oral agents simply have not. When a biologic is prescribed, it is accompanied by patient support programs, manufacturer-provided monitoring tools, and an entire infrastructure of clinical support. When chloroquine is prescribed, the clinician is largely on their own — relying on institutional memory, published protocols, and their own clinical judgment. For a specialty that has grown accustomed to the scaffolding that pharmaceutical companies provide around newer agents, this absence of support can feel like a deterrent.
This dynamic does not reflect conscious bias so much as structural incentive. The pharmaceutical economics of dermatology have shaped training, conference programming, and practice culture in ways that systematically disadvantage older agents regardless of their clinical merits.
The Patient Population Left Behind
The consequences of chloroquine's dermatological invisibility are not evenly distributed. Patients with DLE who lack access to academic medical centers or multidisciplinary lupus clinics are particularly vulnerable to receiving suboptimal care. In rural and underserved communities — where rheumatology access is limited and dermatology practices may serve large geographic catchment areas — the absence of antimalarial prescribing within dermatology creates a tangible gap in care quality.
For these patients, the calculus is straightforward: chloroquine is inexpensive, orally administered, and effective for a condition that, left inadequately treated, causes permanent scarring and significant psychosocial burden. The barriers preventing its use are not clinical. They are structural, educational, and economic.
Toward a More Complete Dermatological Practice
Addressing chloroquine's underutilization in American dermatology requires intervention at multiple levels. Residency programs should incorporate dedicated instruction on antimalarial pharmacology, including practical guidance on dosing, monitoring, and patient selection. Professional society guidelines should be revised to assign antimalarial prescribing authority clearly within dermatology, rather than treating it as a rheumatological responsibility by default.
Perhaps most importantly, dermatologists themselves should feel empowered to reclaim a therapeutic category that is clinically relevant to conditions they manage every day. The evidence supporting chloroquine in photosensitive and cutaneous autoimmune disease is not obscure or contested — it is simply underread within a specialty that has oriented itself away from older pharmacology.
The paradox at the heart of this issue is not that chloroquine is unproven in dermatological disease. It is that the specialty best positioned to deploy it has, through a combination of training gaps, institutional incentives, and cultural drift, effectively written it out of its own practice. Correcting that requires acknowledging the problem first.
